Methylene blue administered EARLY proves to be effective in septic shock patients

Written By : Aditi

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-07-19 04:45 GMT | Update On 2023-07-19 10:34 GMT

Mexico: A study published in BMC Critical Care entitled "Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial" by Miguel Ibarra-Estrada, evaluated the effectiveness of methylene blue (MB) in patients with septic shock. They found that the MB group had a shorter time to vasopressor discontinuation, one more day of vasopressor-free days at day 28, a shorter ICU and hospital stay, and no serious adverse effects related to MB administration.

It is already known that MB has been tested as a rescue therapy for refractory septic shock patients. More data must be collected for optimal timing, dosing and safety.

Researchers assessed whether early adjunctive MB reduces the time to vasopressor discontinuation in septic shock.

Patients were assigned based on Sepsis-3 criteria to MB or placebo. The time to vasopressor discontinuation at 28 days was the primary outcome studied. The secondary results measured in the study were the vasopressor-free days at 28 days, days on a mechanical ventilator, length of stay in ICU and hospital, and mortality at 28 days.

The study results could be summarised as follows:

• There were 91 patients in the study.

• MB and placebo had forty-five, and 46 were assigned to MB and placebo, respectively.

• Among MB patients, there was a shorter time to vasopressor discontinuation (69 h vs 94 h), one more day of vasopressor-free days at day 28, a shorter ICU length of stay by 1.5 days and a shorter hospital length of stay by 2.7 days than control group patients.

• There were similar Days on a mechanical ventilator and mortality.

• No serious adverse effects tied to MB were reported.

Concluding further, they said among septic shock patients, MB, if administered early, reduces vasopressor duration, cumulative fluid balance, and ICU and hospital stay without adverse effects in septic shock patients.

However, continual research is required for confirmation of potential benefits.

Further reading

Ibarra-Estrada, M., Kattan, E., Aguilera-González, P. et al. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Crit Care 27, 110 (2023). https://doi.org/10.1186/s13054-023-04397-7

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Aditi

Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Methylene blue administered EARLY proves to be effective in septic shock patients

Similar News

Developing novel drug for acute MI, acute kidney injury, and subsequent chronic organ failure: Study

15 Percent of COPD Exacerbation Patients Develop Arrhythmias, Tripling In-Hospital Death Risk: Meta-Analysis

Sepsis can kill even previously healthy people if recognized too late, finds study

Long-acting glucocorticoids improves survival of critically ill patients with sepsis: Study

Handheld Ultrasound Proves Effective for VExUS Assessment in Critically Ill Patients: Study

Inhaled Molgramostim Promising for Autoimmune Pulmonary Alveolar Proteinosis: Phase 3 Trial Shows

Pediatric Pain Relief: The Role of Regional Anesthesia in Renal Disease Management, study finds

Shaking Off the Shakes: Study evaluates Ondansetron's Role in Mitigating Etomidate-Induced Myoclonus